← Leaderboards
Svetomir Nenad Markovic
Mayo Clinic
$4,919,014
Attributed
$4,919,014
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,919,014 · 6
By mechanism
R01$3,027,575 · 1
R21$1,882,149 · 3
M01$9,290 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaTumorMetastatic MelanomaMalignant NeoplasmsMediatingCellsNeoplastic CellImmuneImageIn VitroImmunotherapyTranslatingLaboratoriesImmune ResponseClinical TrialsNeoplasm MetastasisBiopsyBaseOperative Surgical ProceduresDetectionDown-RegulationCancer CellCutaneous MelanomaExcision
Grant awards (13)
Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse$1,211,213
R01 · FY2025 · CA · contact PI
Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse$581,811
R01 · FY2024 · CA · contact PI
Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse$610,829
R01 · FY2023 · CA · contact PI
Quantitative assessment of pre-metastatic immune subversion as a risk factor for melanoma relapse$623,722
R01 · FY2022 · CA · contact PI
IL-2 scintigraphy as a guide to cancer immunotherapy$305,895
R21 · FY2013 · CA · contact PI
IL-2 scintigraphy as a guide to cancer immunotherapy$325,420
R21 · FY2012 · CA · contact PI
Systemic auto-immunization against cancer using modified radiofrequency ablation$339,975
R21 · FY2009 · CA · contact PI
Systemic auto-immunization against cancer using modified radiofrequency ablation$339,975
R21 · FY2008 · CA · contact PI
B7-DC Cross-linking antibody immunotherapy$285,593
R21 · FY2008 · CA · contact PI
B7-DC Cross-linking antibody immunotherapy$285,291
R21 · FY2007 · CA · contact PI
DOSE FINDING STUDY OF AEROSOLIZED GM-CSF IN THE TREATMENT OF METASTATIC MELANOMA$948
M01 · FY2005 · RR
Identification of Immunostimulatory Dose of Natural INF$6,952
M01 · FY2004 · RR
Dose of Aerosolized GMCSF in Metastatic Melanoma Therapy$1,390
M01 · FY2004 · RR